Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Neuroblastoma 29Ganglioneuroblastoma 7Osteosarcoma 4Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Rhabdomyosarcoma, Embryonal 1Rhabdomyosarcoma, Alveolar 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Neoplasms 1Neoplasm, Residual 1Medulloblastoma 1Leiomyosarcoma 1Glioma 1Glioblastoma 1Ependymoma 1Diffuse Intrinsic Pontine Glioma 1Brain Neoplasms 1Bone Neoplasms 1

Interventions

Etoposide 154Carboplatin 142Cisplatin 104Topotecan 74durvalumab 48atezolizumab 46Irinotecan 44pembrolizumab 39Paclitaxel 34Nivolumab 33Radiotherapy 29anlotinib 23PM 01183 22Gemcitabine 21Drug Therapy 20apatinib 19Ipilimumab 18Docetaxel 17Temozolomide 16Platinum 16Radiosurgery 15Pemetrexed 14toripalimab 13tislelizumab 13olaparib 13Bevacizumab 13amrubicin 11Magnetic Resonance Spectroscopy 11Cyclophosphamide 11rovalpituzumab tesirine 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Small Cell Lung Carcinoma × dinutuximab × Clear all
NCT03098030 2020-12-09

Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Cancer

United Therapeutics

Phase 2/3 Completed
483 enrolled 19 charts
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡